

# **ENDEAVOR IV**


**Two-Year Follow-up from a Prospective  
Randomized Trial Comparing a  
Zotarolimus-Eluting Stent and a  
Paclitaxel-Eluting Stent in Patients with  
Coronary Artery Disease**

**Martin B. Leon, MD**  
**for the Endeavor IV investigators**

*Columbia University Medical Center  
Cardiovascular Research Foundation  
New York City*

# ENDEAVOR IV – 2yr FU

*Clinical Trial Design*  
*PI: Martin B. Leon*



# ENDEAVOR IV – thru 1yr FU


## *Summary Findings*

*The Endeavor DES, compared with the Taxus DES, demonstrated...*

- **Angiographic results**
  - Higher angio late loss at 8 mos FU
- **Clinical outcomes**
  - Reduced peri-procedural non-Q MIs, and a similar overall safety profile (death, Q-MI, and stent thrombosis) thru 12 mos FU
  - Similar TVF (1<sup>ry</sup> endpoint) thru 12 mos FU
  - Similar TVR/TLR in subsets of interest (including diabetics) thru 12 mos FU, especially in the patient cohort with only clinical FU


# ENDEAVOR IV – 2yr FU

## *Patient Flow Chart*




# ENDEAVOR IV – 2yr FU

## *Efficacy Endpoints 12-24 months*




# ENDEAVOR IV – 2yr FU

## Safety Endpoints 12-24 months



# ENDEAVOR IV – 2yr FU


## ARC Def/Prob ST 12-24 mos (VLST)



Endeavor	726	726	709	705	699
Taxus	725	725	706	703	699

# ENDEAVOR IV – 2yr FU

## Myocardial Infarction 12-24 mos



Endeavor	726	726	707	703	697
Taxus	725	725	706	702	697



# ENDEAVOR IV – 2yr FU

## *Conclusions*

*Between 12 and 24 mos FU, the Endeavor DES, compared with the Taxus DES, demonstrated...*

- **Efficacy**
  - Continued similar TLR and TVR, even in high restenosis risk subgroups (e.g. diabetics) and especially in the patients with only clinical FU
- **Safety**
  - Reduced ARC def/prob very late stent thrombosis (P=0.059; 1 vs. 6 events), even in the setting of frequent DAPT use
  - Reduced all MIs (P=0.023), linked to the decrease in very late stent thrombosis events
  - Safety findings consistent with the larger pooled analysis of Endeavor studies